key: cord-0700793-1962yb16
authors: Han, Jinming; Chitu, Violeta; Stanley, E. Richard; Wszolek, Zbigniew K.; Karrenbauer, Virginija Danylaité; Harris, Robert A.
title: Inhibition of colony stimulating factor-1 receptor (CSF-1R) as a potential therapeutic strategy for neurodegenerative diseases: opportunities and challenges
date: 2022-04-02
journal: Cell Mol Life Sci
DOI: 10.1007/s00018-022-04225-1
sha: 84035157f4867f33ff5168431ac423c428fbc7ae
doc_id: 700793
cord_uid: 1962yb16

Microglia are specialized dynamic immune cells in the central nervous system (CNS) that plays a crucial role in brain homeostasis and in disease states. Persistent neuroinflammation is considered a hallmark of many neurodegenerative diseases, including Alzheimer’s disease (AD), Parkinson's disease (PD), Huntington’s disease (HD), amyotrophic lateral sclerosis (ALS) and primary progressive multiple sclerosis (MS). Colony stimulating factor 1-receptor (CSF-1R) is predominantly expressed on microglia and its expression is significantly increased in neurodegenerative diseases. Cumulative findings have indicated that CSF-1R inhibitors can have beneficial effects in preclinical neurodegenerative disease models. Research using CSF-1R inhibitors has now been extended into non-human primates and humans. This review article summarizes the most recent advances using CSF-1R inhibitors in different neurodegenerative conditions including AD, PD, HD, ALS and MS. Potential challenges for translating these findings into clinical practice are presented.

Microglia are the predominant resident immune cells of the central nervous system (CNS), deriving from yolk sac progenitors during early neurodevelopment [1] [2] [3] [4] . Under steady-state conditions, they actively contribute to myelinogenesis [5] and synaptic pruning [6] . Upon detection of non-homeostatic disturbances microglia become rapidly activated and proliferate. They develop into a broad range of activation states depending on the disease stage [7] [8] [9] [10] and microenvironment [11] [12] [13] . It is generally accepted that initial activation of microglia may exert beneficial effects on disease recovery by phagocytosing cellular and myelin debris and favoring remyelination which in turn is thought to limit axonal dysfunction and loss [14] . In contrast, prolonged microglial activation may contribute to chronic neuronal damage and impede regeneration [15] [16] [17] . Emerging data suggest that microglial activation is a hallmark of a number of neurodegenerative diseases, including Alzheimer's disease (AD) [18, 19] , Parkinson's disease (PD) [20], Huntington's disease (HD) [21] , amyotrophic lateral sclerosis (ALS) [22, 23] and primary progressive multiple sclerosis (MS) [24, 25] . Furthermore, a variety of genes identified as risk factors for neurodegenerative diseases are expressed in microglia [26] . Developing strategies for replacing defective microglia or modulating microglial function may therefore be a novel approach to treat neurodegenerative diseases [27] [28] [29] . As our understanding is rapidly evolving, we herein focus on the most updated preclinical and clinical evidence regarding potential microglia-based therapy in neurodegenerative diseases through targeting of the colony stimulating factor-1 receptor (CSF-1R).

CSF-1R is a receptor tyrosine kinase belonging to the platelet-derived growth factor receptor (PDGFR) family [30] . CSF-1R can be activated by two different homodimeric ligands, CSF-1 (also known as macrophage-colony stimulating factor, M-CSF) and interleukin-34 (IL-34) which have limited (~ 10%) primary sequence homology but share a similar three-dimensional structure and bind the same site on the CSF-1R [30] . While CSF-1R appears to be the sole receptor for CSF-1, IL-34 also binds receptor protein-tyrosine phosphatase-ζ (RPTP-ζ) [31] . The ligands also differ in their pattern of expression. Within the central nervous system (CNS), CSF-1 is predominantly expressed in the corpus callosum, cerebellum and areas of the olfactory bulb, cortex and hippocampus, while IL-34 is expressed throughout the forebrain but at very low levels in the cerebellum [32] [33] [34] . Physiologically, CSF-1 is essential for embryonic microglial development, while IL-34 is mainly involved in their post-natal development and maintenance [35, 36] . CSF-1 and IL-34 may regulate the development and maintenance of different subpopulations of microglia. In mice, neither developmental genetic targeting nor function blocking antibodies to either CSF-1 or IL-34 cause a complete loss of brain microglia [32-34, 37, 38] . Instead, they result in a region-specific loss that corresponds to the complementary expression patterns of each ligand [39] . Interestingly, CSF-1R signaling and the expression of CSF-1 can be significantly upregulated during inflammatory conditions [16, 40] , with CSF-1 expression being upregulated in disease-associated microglia [7] and possibly contributing, in an autocrine fashion, to their expansion.

Structurally 

Within the CNS, the CSF-1R is mainly expressed on microglia and plays an important role in microglial development and steady-state maintenance [1, 44, 45] .

Genetic ablation or loss of function of the CSF-1R causes depletion of microglia in mice [1] , zebrafish and man [46] , confirming that, regardless of species, the survival, maintenance and proliferation of microglia are critically dependent on CSF-1R. Consistent with this, microglia can be effectively ablated using CSF-1R kinase inhibitors [28, 45, 47] . Recently, several CSF-1R inhibitors, including PLX3397 (Pexidartinib; Plexxikon, Inc.) [48] , PLX5622 (Plexxikon Inc.) [49] , BLZ945 (Novartis) [50] , sCSF-1R inh (Sanofi) [16] , Ki20227 [51, 52] , JNJ-40346527 (Johnson & Johnson) [53, 54] , ARRY-382 (Array BioPharma) [54] or GW2850 [55, 56] have been tested in preclinical studies and clinical trials for a variety of conditions. Among these, Pexidartinib and PLX5622 have been the most widely used in rodent model research [45, 57, 58] , which has been extended into non-human primates [59] . Pexidartinib is orally bioavailable, brainpenetrant [60] and exhibits a favorable tolerability and safety profile in human studies [54, 61] . Apart from targeting CSF-1R and c-Kit, Pexidartinib (PLX3397) shows limited cross reactivity with other tyrosine kinases and has 10 ~ 100-fold selectivity for c-Kit and CSF1R over other related kinases, including PDGFRα and FLT3 [62, 63] . PLX3397 binds to the autoinhibited CSF-1R through direct interactions with juxtamembrane residues embedded in the ATP-binding pocket and prevents ATP and substrate binding [63] . Consistent with this, PLX3397 efficiently suppresses the proliferation of CSF-1-dependent microglia and macrophage cell lines in vitro [63] and its administration in vivo induces a rapid loss of microglia [45] . More selective CSF-1R inhibitors including PLX5622 and GW2580 (PLX6134) have also been used to eliminate microglia and CSF-1-dependent macrophages in various research settings [64, 65] . PLX5622 is a novel CSF-1R inhibitor with a higher selectivity and brain penetrance than PLX3397 ( Fig. 1 ) (reviewed in [66] ). PLX3397 and PLX5622 can be integrated into rodent chow diet at different concentrations without significantly affecting adult mice behavior or cognitive functions [45, 66, 67] . JTE-952 is a highly specific and orally available CSF-1R inhibitor, with a relatively higher efficacy than GW2580 [40, 68] . CSF-1R signaling pathways and the effects of CSF-1R inhibitors. CSF-1 and IL-34 share a common receptor, CSF-1R. After binding to the CSF-1R, a cascade of downstream signaling molecules is activated, including those involved in the PI3K-AKT, ERK1/2 and JAK/STAT signaling pathways, promoting cellular proliferation, survival and differentiation. PLX3397 (Pexidartinib) and PLX5622 are the most widely used CSF-1R inhibitors, with favorable tolerability profiles. Treatment with PLX3397, or PLX5622, causes effective depletion of microglia. PLX3397 also inhibits C-KIT, PDGFRα and FLT3. Consequently, in clinical practice, the broader effects of PLX3397 may cause adverse effects, including hair discoloration and hepatotoxicity. PLX5622 is a novel CSF-1R inhibitor with a higher selectivity. (-) indicate inhibitor-induced reduction in signaling through the respective pathways

We have previously demonstrated that approximately 95% of CD11b + CD45 low Ly6C − Ly6G − microglia can be effectively depleted after 21 days of PLX3397 treatment at a concentration of 290 mg/kg [69] . Withdrawal of these compounds in mice causes a rapid microglial repopulation solely derived from surviving resident microglia, rather than from Nestin + stem cells [70] . Subsequently, there is an overshoot in repopulating microglial numbers, which become normalized to the baseline level after 3 weeks [71] . Other studies have indicated that both chronic and transient depletion of activated (senescent) microglia by CSF1R inhibitors may exert beneficial effects in aging by reducing inflammation, metabolic decline [49] and by reversing the changes in hippocampal neuronal complexity [71] . Importantly, the surviving resident microglia following CSF-1R inhibitor treatment have a remarkable capacity to regenerate the CNS and the newly repopulated microglia acquire a more homeostatic phenotype and can promote brain repair [27, 71, 72] . Thus, at least in mouse models of aging, CSF-1R inhibitors permit the elimination of activated microglia and their replacement by newly generated, more homeostatic microglia.

AD is the most common human neurodegenerative disease. Clinically, late-onset AD affects individuals over the age of 65 years, with the prevalence of early-onset patients being relatively low [73] . The hallmarks of AD pathology are the presence of extracellular amyloid beta (Aβ) and intraneuronal accumulation of fibrillar tangles of abnormally phosphorylated Tau (pTau) protein in the brain [74, 75] . The accumulation of insoluble and highly phosphorylated tau species that are assumed to be pathologically relevant can be detected by phosphorylation-dependent antibodies such as AT8 (phospho-Ser202 and phospho-Thr205), PHF1 (phospho-Ser396 and phospho-Ser404), and AT270 (phospho-Thr181) and the staging of AD cases is based on the staining of pTau Ser202/Thr205 with the specific antibody AT8 [76] .

A widely used AD model is the 5xFAD mouse [77] , in which the expression of 5 human familial AD disease mutations is driven by the Thy1 promoter. In these mice, neuritic plaque deposition is evident at 2 months and neuronal loss starts from 10 months of age [57, [78] [79] [80] . Other models include the APP/PS1 transgenic mice expressing APP Swe and PS1 mutations, the 3xTg-AD mice expressing the APP Swe , MAPT P301L and PSEN1 M146V transgenes. Models of AD tauopathy include the MAPT P301S mice, expressing the mutant form of human Tau, the TE4 knock-in mice, expressing Tau P301S and human ApoE4 and Tg4510 mice, expressing the P301L mutation. Studies in these models indicate that neuroinflammation plays an important role in the pathogenesis of AD, with microglia enacting a primary role [81] [82] [83] . In addition, resolution of inflammation, a tightly regulated process mediated by specialized proresolving lipid mediators to prevent over-responsiveness to tissue damage and infection, has been reported to be defective in AD patients [84, 85] .

Mutations in APOE or TREM2 genes expressed in microglia are strongly linked to an increased risk of developing AD [86] [87] [88] [89] . Reactive/phagocytic microglia surrounding extracellular plaques promote Aβ plaque expansion [90] . In preclinical studies of AD, total or partial removal of microglia using CSF-1R inhibitors improved cognition (Table 1) . Following CSF-1R inhibitor treatment, both a decrease [47, 58, 78, 91] and no change [57, 67, 92] in Aβ plaque load have been reported, respectively, and the effects on Tau pathology and phosphorylation were also variable. Microglial depletion at 4 or 6 months of age using PLX3397 caused a remarkable reduction of AT8 + pTau in two different tauopathy mouse models [93] . In another study, the same inhibitor attenuated the progression of pTau and halted brain atrophy in TE4 mice [94] . However, administration of a comparable dose of PLX3397 in older (12-month-old) Tg4510 mice produced only a 30% reduction in microglia numbers and failed to elicit changes in Tau pathology and phosphorylation [95] . Regardless of the extent of microglial depletion, or effects on Aβ and Tau, most studies agree that treatment with CSF-1R inhibitors decreases inflammation in AD [57, 67, 78, 91, 92] . Together, these data indicate that activated microglia, rather than Tau or Aβ direct neurotoxicity, mediate neurodegeneration in AD and suggest CSF-1R inhibitors as a potential therapeutic strategy in AD. However, since a small number of neurons, including mature forebrain cortical neurons and hippocampal neurons may express CSF-1R [96] [97] [98] , the effects of CSF-1R inhibition on the accumulation of intraneuronal amyloid should also be investigated.

Interestingly, the effectiveness of microglial depletion following CSF-1R inhibitors in AD varies between studies and brain regions. Unlike the near complete ablation of microglia within a few days using PLX5622 in wild-type mice, microglial densities were depleted by only 30% in the subiculum and by 70% in the thalamus in 5xFAD mice [91] . Consistently, following PLX5562 treatment, deposited amyloid as assessed by immunostaining (6E10) was significantly decreased in the thalamus, where microglia were effectively removed, but not in the subiculum [91] , suggesting that a near complete depletion of microglia following CSF-1R inhibitor treatment, but not a modest reduction, may exert beneficial effects in preclinical AD models (Table 1) . Intriguingly, the presence of CSF-1R-inhibitor resistant microglia [99] , associated with dense core plaques, was reported in the 5xFAD mouse model [57] . The factors contributing to the maintenance of these CSF-1R-inhibitor resistant microglia and their [53] 5xfAD mice (9 months old) PLX3397 (50 mg/kg, oral gavage)

Alleviated Aβ pathology in the cortex and hippocampus Increased the expression of synapse-related protein Rescued dopaminergic signaling [47] TE4 mice (6 months old)

Rescued the brain volume loss Reduced ptau levels Recued soluble apoE level in TE4 mice [94] AAV-GFP/tau-injected mice (4 months) and PS19 mice (3.5 months) PLX3397 (290 mg/kg) 86% Inhibited tau propagation in the dentate gyrus [93] 5xFAD mice (1.5 months)

PLX5622 (1200 mg/kg) 97-100% Reduced plaque number and volume Prevented the downregulation of synaptic genes in the hippocampus [58] functional role in neurodegenerative diseases should be investigated.

After AD, PD is the second most prevalent neurodegenerative disease worldwide and it is characterized by progressive degeneration of dopaminergic neurons in the substantia nigra of the midbrain [100] . Most PD patients develop their clinical symptoms over the age of 60 and some cases can be caused by mutations in genes, including PRKN, SNCA and LRRK2 [101, 102] . The significant loss of dopamine leads to classical idiopathic PD disease-like movement problems. Apart from typical clinical manifestations including rigidity, bradykinesia, resting tremors and postural instability, patients with PD also suffer from non-motor symptoms such as mood and sleep disorders [103] . PD is viewed as a multisystem disorder with complex mechanisms developing with disease progression. Levodopa is the gold-standard symptomatic treatment for PD. Most patients may experience motor complications after long-term treatment. Alternative potential therapeutic strategies to treat PD represent a current unmet medical need. Neuroinflammation mediated by glial cells plays a pivotal role in the pathogenesis of PD and immune-targeted therapeutic strategies for treating PD are currently being tested [104] . Microglial functions are tightly controlled by neuronal activity and neurotransmitters secreted by healthy neurons [105, 106] . The death of dopaminergic neurons may cause microglia to lose their physiological functions and develop a pathological microglial phenotype [107] . The increased microglial activation measured by positron emission tomography (PET) during early PD disease stages has been reported to be inversely correlated with the loss of dopamine terminals [108] . Furthermore, persistent and uncontrolled stimuli, such as the accumulation of α-synuclein, also contribute to chronic neuroinflammation [109] . Microglia carrying PD genetic variants may fail to degrade cell debris, unfolded proteins and dying neurons due to endolysosomal impairments and dysfunctional phagocytosis [110] . Collectively, emerging evidence suggests that microglia can be targeted pharmacologically to prevent or delay PD [111, 112] .

In a preclinical model of PD induced by stereotaxic injection of 6-hydroxydopa (6-OHDA), PLX3397 treatment at a concentration of 30 mg/kg initiated 7 days after the neurotoxic insult exerted a neuroprotective influence [113] . Specifically, both motor function and depressive-like behavior were alleviated following PLX3397 treatment, as measured by the adhesive removal test and forced swim test, respectively [113] . Strikingly, functional PET imaging demonstrated that PD rats treated with PLX3397 exhibited a lower uptake of radioactive translocator protein, a marker for neuroinflammation and glial activation, than did the PD group [113] . Although there are minor changes of dopamine transporters in PD rats following PLX3397 treatment, an increased tracer uptake was recorded in the treatment group as measured by dopaminergic and glutamatergic PET [113] . These results indicated that the therapeutic effects of CSF-1R inhibitors in PD can be achieved by reducing proinflammatory mediators. However, in another study of 4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced PD in mice, PLX3397-mediated depletion of microglia before the neurotoxic insult worsened locomotor performance and enhanced dopaminergic neurotoxicity and leukocyte infiltration, indicating a neuroprotective role of microglia in PD [62] . We propose that the differences in timing of microglial depletion (i.e. before, or after the injury of the dopaminergic system) might explain some of these described discrepancies.

The long-term safety and efficacy of CSF-1R inhibitors in PD remain to be further explored. If the dynamics of microglial responses during the initiation and progression in PD can be better understood, reactive microglia may then be targeted using CSF-1R inhibitor treatment within an appropriate time window.

HD is an autosomal dominant devastating neurodegenerative disorder resulting from the abnormal CAG trinucleotide expansion (36 repeats or more) in exon 1 of the huntingtin (HTT) gene, encoding a long polyglutamine tract of the huntingtin protein [114, 115] . The mean age at onset of typical HD symptoms is 30-50 years and disease onset is inversely correlated with the length of the CAG repeat [115] . Individuals with HD usually experience late-manifesting movement disorders, cognitive decline, behavioral abnormalities and psychiatric disturbances [115] . HD patient-reported symptoms include emotional issues, fatigue, difficulty thinking and daytime sleepiness [116] . It is well established that the degeneration of the striatum and widespread cortical atrophy with neuronal loss are hallmarks of HD brain pathology [117] . It is also important to note that neurodevelopment can be affected in the context of HD [118] . This finding was supported by abnormal HTT being mis-localized in the embryo, disrupting neuroepithelial junctional complexes and then shifting neurogenesis towards the neuronal lineage [118] .

There are no effective treatments for HD, but modulation of immune activation to prevent or delay HD has recently attracted considerable attention [119, 120] . Neuroinflammation has a role in the pathogenesis of HD. Specifically, the presence of reactive microglia was noted in the striatum and cortex of HD human brains [117] . Furthermore, microglial activation was evident even before HD symptom onset, suggesting that these cells play an essential role in the progression of HD [121] . Indeed, neuronal mutant HTT (mHTT)-mediated neurotoxicity has been linked to increased numbers of microglia with a reactive phenotype, subsequently leading to cell death [117] . Cell-autonomous mechanisms induced by the intrinsic mutant protein also play a contributory role in HD-related microglial activation [122] . However, microglia have also been reported to suppress inflammation and to preserve neuronal function in the HD brain [117] .

The role of CSF-1R-dependent microglia in HD has been explored in transgenic R6/2 mice expressing the human HTT gene containing more than 100 CAG repeats [123] . These mice experience progressive motor and behavioral abnormalities starting at 7 weeks of age. Increased Iba1 + microglial densities are evident in specific brain regions [123] . Sustained PLX3397 treatment at a concentration of 275 mg/kg starting at week 6 in R6/2 mice, significantly attenuated HD-related grip strength and object recognition deficits and normalized their dysregulated interferon gene signature [123] . Furthermore, PLX3397 treatment reduced the accumulation of mutant huntingtin (mHTT) by decreasing the numbers of intranuclear mHTT inclusion bodies in the striatum, without exerting significant influences on HTT gene expression. In addition, following sustained treatment, significant striatal volume loss was inhibited, independent of NeuN + density changes and abnormal accumulation of chondroitin sulphate proteoglycans, primary components of glial scars, was significantly attenuated in the striatum, cortex and hippocampus [123] .

Emerging data suggests that systemic administration of CSF-1R inhibitors at a relatively high dose exerts crucial influences on peripheral tissue macrophages [124, 125] . It is therefore possible that attenuation of HD disease-related behavioral functions in R6/2 mice following long-term PLX3397 treatment could at least in part be attributed to a decreased number of muscle macrophages. Collectively, these results suggest that targeting CSF-1R would be beneficial in HD. However, there are several shortcomings associated with the use of genetically modified small animal models to model the complex pathogenesis of HD. Small animal models fail to mimic the selective cortical and striatal neurodegeneration caused by ubiquitously expressed mHTT and striking neurodegeneration is not evident in transgenic mice expressing small N-terminal Htt repeats [126] . In addition, HTT may function differently in small and large animal brains. The HD monkey model exhibits clinical symptoms, including dystonia and chorea, and pathogenic features, including nuclear inclusions and neuropil aggregates, which are lacking in the transgenic mice generated using the same approach [127] . A novel huntingtin knock-in pig model [128] may serve as an important tool to validate the promising findings achieved using CSF-1R inhibitors in the rodent model of HD.

Other approaches using human materials such as biopsyor iPSC-derived microglia and monocyte-derived microglialike cells [129] may also help us to better understand the pathogenesis of HD in the future.

ALS is a rapidly progressive neurodegenerative disorder with limited treatment options, caused by genetic and noninheritable components that lead to significant loss of upper and lower motor neurons in the brainstem, motor cortex and spinal cord, and ending with respiratory muscle dysfunction [130] . ALS usually develops between the ages of 40 and 70. A variety of genes including superoxide dismutase 1 (sod1), transactive response DNA-binding protein 43 (tdp-43) and chromosome 9 open reading frame 72 (c9orf72) have been linked to the pathogenesis of ALS [131] . Transgenic rodent models expressing these genes can develop an ALS-like disease and SOD1 G93A mice are commonly used to explore ALS pathogenesis [132] . ALS is a heterogeneous illness involving oxidative stress, impaired autophagy, dysfunctional mitochondria and misfolding of proteins [133] [134] [135] .

Although ALS is not initiated by inflammatory responses, neuroinflammation mediated by reactive glial cells and infiltrating leukocytes is increasingly recognized as a prominent pathological feature of ALS [131, 136, 137] . In support of this, widespread microglial activation as measured by PET is evident in ALS [138] and changes of microglial genes may occur before motor neuron damage [139] . Activated microglia have also been suggested to serve as a potential source of aberrant extracellular microRNAs contributing to neurodegeneration in ALS [140] . In addition, circulating monocytes from individuals with ALS are skewed towards a pro-inflammatory state [141] . Thus, efforts to reverse dysfunctional myeloid cells in ALS represent a potential therapeutic goal.

A pioneering study has indicated that treatment with the CSF-1R inhibitor GW2580 has beneficial effects in SOD1 G93A mice [142] . In this model, increased expression of CSF-1R and CSF-1, but not IL-34, was recorded in the spinal cord during pathogenesis [142] . GW2580 treatment through oral gavage starting from 8 weeks of age significantly depleted activated microglia and attenuated ALSrelated motor deficits, as measured by rotarod testing and treadmill tests [142] . Strikingly, treatment with the CSF-1R inhibitor significantly increased the survival of SOD1 G93A mice, extending the maximal lifespan by 12% [142] . GW2580 treatment also reduced the numbers of circulating monocytes and their influx into the tibial nerve in SOD1 G93A mice, suggesting that peripheral immunity also plays a role in ALS [142] . Indeed, suppression of pro-oxidative function in the peripheral myeloid cells of SOD1 G93A mice (by genetic targeting of Nox2 or overexpression of wild-type human SOD1) reduced the proinflammatory activation of microglia, delayed symptoms and increased survival [143] . In summary, CSF-1R inhibition may slow the disease progression of SOD1 G93A mice by targeting both central and peripheral immunity.

However, the SOD1 G93A mouse model only recapitulates a small subpopulation of ALS patients, with > 90% patients developing sporadic disease [139] . Additional investigations are thus needed to validate the beneficial outcomes of CSF-1R inhibitor treatment in ALS. Importantly, an open-label phase 2 clinical trial investigating the safety and tolerability of the CSF-1R inhibitor BLZ945 in patients with ALS is ongoing (ClinicalTrials.gov, identifier: NCT04066244).

MS is a chronic demyelinating disease, with inflammation being the predominant neuropathological feature during the early course-relapsing-remitting disease phase [144] . It is well accepted that major differences exist between relapsing-remitting and primary progressive MS, but there are no clear clinical, radiological or biological boundaries of MS phenotype separation. Recently, a novel objective automatic classifier has been proposed using clinical information for assessing the MS phenotype, yielding a relatively high accuracy [145] that may be beneficial for further research. Progressive types of MS are characterized by irreversible accumulation of neurological disability which is mainly driven by neurodegeneration [146] . Individuals with primary progressive MS are usually diagnosed after the age of 40. Although it declines with age, neuroinflammation is still evident in some progressive MS individuals with clinical or radiological evidence of disease activity [147, 148] . Chronic activation of microglia contributes to neuroinflammation and neurodegeneration in MS [149] . In support of this, widespread abnormal glial activation was observed in progressive MS, as measured by 18 F-PBR06 PET imaging [25, 150] .

Levels of CSF-1R and its ligand, CSF-1, in CNS tissues are significantly increased in both preclinical mouse models and in MS patients [16] . Strikingly, selective inhibition of CSF-1R using a CNS-penetrant small molecule inhibitor, sCSF-1R inh , markedly attenuated disease severity, particularly during disease progression, in the preclinical models, mainly by reducing neuroinflammation, axonal degeneration and the production of proinflammatory cytokines [16] . Consistently, pharmacological depletion of microglia using another CSF-1R inhibitor (BLZ945) in the murine cuprizone model of demyelination effectively enhanced remyelination in a brain region-specific manner [50] . These beneficial effects on remyelination and disease recovery following the inhibition of CSF-1R have been reproduced in later studies using two other inhibitors (PLX3397 or PLX5622) [151, 152] . Thus, inhibiting CSF-1R in progressive MS populations during an early disease stage is an attractive treatment option.

Microglia play a well-documented role in regulating synapse development and connectivity [153] . Removing microglia using CSF-1R inhibitors during critical neurodevelopmental periods could cause potential side effects. For example, elimination of microglia using PLX5622 beginning at embryonic day 3.5 (E3.5) and ending at E15.5 increased the numbers of active cleaved Caspase 3 + apoptotic cells in the developing hypothalamus [154] and produced female-specific long-term behavioral alterations, with juvenile mice becoming hyperactive and adult mice exhibiting anxiolytic-like behavior [154] . Notably, mouse pups exposed to PLX5622 in utero also suffered from craniofacial and dental defects due to non-CNS effects on macrophages and osteoclasts [154] .

CSF-1R inhibition might also be harmful during the early postnatal period. Two-week PLX3397 treatment starting at postnatal day 14 significantly increased dendritic spine density in the primary visual cortex, and changed spontaneous synaptic activity, subsequently disrupting cortical plasticity [155] . These results indicate that CSF-1R inhibitor treatment during development may alter functional connectivity in the CNS. In addition, treatment of mice with BLZ945 during the early postnatal period dramatically reduced the number of oligodendrocyte progenitors [5] .

Importantly, detrimental effects of CSF-1R inhibition in adults have also been reported. Acute genetic microglial depletion in adult mice leads to neurodegeneration in the somatosensory system, associated with a type I interferon signature [156] . Transient PLX5622-mediated depletion of microglia in adult mice impaired the integration of adult-born granule cells in the olfactory bulb circuit and caused reduced odor-evoked responses [157] and ablation of microglia might cause seizures by influencing the activity of neurons [106] . Furthermore, PLX3397 or PLX5622 treatment reduces the numbers of PDGFRα + or NG2 + oligodendrocyte progenitor cells, but not of mature oligodendrocyte cells [158] . Furthermore, administration of CSF-1R inhibitors to adult mice causes significant loss, not only of microglia, but also of ~ 60% of brain-resident perivascular macrophages [159] .

In summary, potential side effects of CSF-1R inhibitor treatment should be carefully considered, particularly during organogenesis and neurodevelopment.

Administration of anti-CSF-1 antibody to mice during the first 60 days of life induces phenotypes similar to those reported in CSF-1-and CSF-1R-deficient mice, including decreased growth rate osteopetrosis associated with decreased osteoclast numbers and decreased macrophage densities in bone marrow, liver, dermis, synovium and kidney and decreased adipocyte size in the adipose tissue [160] . Administration of CSF-1R inhibitors to adult mice also affects monocyte maturation and causes the loss of several peripheral tissue macrophages including those present in the liver, spleen and sciatic nerves [64, 161] . Furthermore, both PLX5622 and PLX3397 significantly reduced numbers of circulating Gr1 low (Ly6C − ) monocytes [125] . Consistent with its broader specificity, PLX3397 treatment at a dose of 400 mg/kg markedly altered the blood cell composition by decreasing the numbers of red blood cells, hemoglobin, platelets, and dendritic cells [94] . CSF-1R inhibitors also exert important effects on trabecular bone density in adult mice [162] . The potential peripheral consequences following CSF-1R inhibitors should be carefully considered.

Of disease and translational research relevance, another major concern would be the toxicity of long-term therapeutic administration of CSF-1R inhibitors. In 2019, Pexidartinib (PLX3397) was approved by the Food and Drug Administration (FDA) for the treatment of selected adult individuals with tenosynovial giant cell tumors (a connective tissue disease driven by CSF-1 in an autocrine manner) [163, 164] . The recommended oral dose is 400 mg twice per day in clinical practice. In a phase 3 clinical trial several adverse events following more than 20 weeks' Pexidartinib treatment were reported [164] , the most common of these being hair discoloration (67%) [163] . We and others have noted similar phenomena in preclinical mouse models treated with PLX3397 [69, 165] . It was suggested that changes of hair color might be attributed to the inhibition of C-KIT [163] . Importantly, Pexidartinib may also cause hepatotoxicity such as reversible raised levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) due to effects on Kupffer cells, the resident macrophages in the liver [163] . All cases were reversible upon discontinuation of the drug without functional liver damage or structural damage to hepatocytes [54] . It is important to note that CSF-1R inhibitors are usually supplied via the diet in preclinical research settings [71] . It was shown that food intake (either high or low-fat) altered exposure as well as pharmacokinetics. Furthermore, it was suggested that these alterations could be alleviated by taking the drugs on an empty stomach or a few hours after a meal [166] .

A study reporting that microglial depletion using PLX5622 in a mouse model of prion disease resulted in prion accumulation and acceleration of disease [167] , raises concerns that CSF-1R inhibitors may exacerbate prion diseases, such as Creutzfeldt-Jakob disease (CJD), fatal familial insomnia (FFI) or Gerstmann-Sträussler-Scheinker disease (GSS).

CSF-1R inhibitors may also cause or exacerbate pathogenic infection of the CNS. Blocking CSF-1R selectively inhibited Th2 memory function in a mouse model of chronic asthma [168] . Other preclinical studies indicate deleterious effects of CSF-1R inhibition in viral infections. Infection of Theiler's murine encephalomyelitis virus (TMEV) in C57BL/6J mice, a preclinical model of spontaneous recurrent seizures, is typically cleared within 14 days. However, TMEV infection in mice depleted of microglia following treatment with PLX5622 leads to fatal viral encephalitis, even after infection with low viral loads [169] . Similarly, in mice infected with a neurotropic strain of mouse hepatitis virus (a group 2 coronavirus), PLX5622 treatment delayed clearance of the virus and increased viral protein load in neurons [170] and herpes simplex virus 1 infection in mice in which the CSF-1R was conditionally deleted decreased survival rate and the ability to control the viral replication [171] . These results suggest that the use of CSF-1R inhibitors might suppress the antiviral response of the CNS [169, 170] and poses a challenge for clinical management of patients and care settings, particularly during the current COVID-19 pandemic [172] .

Despite promising results from preclinical studies with CSF-1R inhibitors, we are still facing the challenge of translating these findings into clinical practice. The failure of antiinflammatory treatments involving global elimination of microglia in neurodegenerative diseases, suggests that dysfunctional microglia might need to be targeted in a spatiotemporally controlled manner. This approach would require investigation of their heterogeneity and functional plasticity in different stages of the disease. CSF-1R inhibitors were mostly tested in preclinical studies during a pre-symptomatic period, or even before onset. However, most patients with neurodegenerative diseases might not be identified until an advanced disease stage. From a clinical perspective, more investigations should be performed at distinct disease stages (e.g. early versus late) to provide convincing evidence of efficacy. CSF-1R inhibition should be attempted in relatively old (> 6 months of age) rather than young mice. Furthermore, potential off-targets effects need to be addressed, especially in studies involving the oral administration of CSF-1R inhibitors. Data availability Data sharing is not applicable to this article as no datasets were generated or analysed during the current study. Ethical approval Not applicable.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http:// creat iveco mmons. org/ licen ses/ by/4. 0/. 

Fate mapping analysis reveals that adult microglia derive from primitive macrophages

Microglia biology: one century of evolving concepts

Cien anos de microglia: milestones in a century of microglial research

Microglia: lifelong patrolling immune cells of the brain

Microglia contribute to normal myelinogenesis and to oligodendrocyte progenitor maintenance during adulthood

New insights on the role of microglia in synaptic pruning in health and disease

A unique microglia type associated with restricting development of Alzheimer's disease

Temporal tracking of microglia activation in neurodegeneration at singlecell resolution

The TREM2-APOE pathway drives the transcriptional phenotype of dysfunctional microglia in neurodegenerative diseases

Spinal cord injury induces permanent re-programming of microglia into a diseaseassociated state which contributes to functional recovery

Diverse brain myeloid expression profiles reveal distinct microglial activation states and aspects of Alzheimer's disease not evident in mouse models

Epigenetic regulation of brain region-specific microglia clearance activity

Microglial homeostasis requires balanced CSF-1/CSF-2 receptor signaling

The pro-remyelination properties of microglia in the central nervous system

Why microglia kill neurons after neural disorders? The friendly fire hypothesis

Inhibition of colony-stimulating factor 1 receptor by PLX3397 prevents amyloid beta pathology and rescues dopaminergic signaling in aging 5xFAD mice

Microglia exacerbate white matter injury via complement C3/C3aR pathway after hypoperfusion

CSF1R inhibitor PLX5622 and environmental enrichment additively improve metabolic outcomes in middle-aged female mice

Brain region-specific enhancement of remyelination and prevention of demyelination by the CSF1R kinase inhibitor BLZ945

Inhibited CSF1R alleviates ischemia injury via inhibition of microglia M1 polarization and NLRP3 pathway

The selective M-CSF receptor tyrosine kinase inhibitor Ki20227 suppresses experimental autoimmune encephalomyelitis

CSF1R inhibitor JNJ-40346527 attenuates microglial proliferation and neurodegeneration in P301S mice

Ruttinger D (2017) Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy

CSF1R inhibition reduces microglia proliferation, promotes tissue preservation and improves motor recovery after spinal cord injury

Tyrosine kinase inhibitors ameliorate autoimmune encephalomyelitis in a mouse model of multiple sclerosis

Eliminating microglia in Alzheimer's mice prevents neuronal loss without modulating amyloid-beta pathology

Sustained microglial depletion with CSF1R inhibitor impairs parenchymal plaque development in an Alzheimer's disease model

Microglial depletion and activation: a [(11)C]PBR28 PET study in nonhuman primates

Cerebrospinal fluid penetration of the colony-stimulating factor-1 receptor (CSF-1R) inhibitor, pexidartinib

Orally administered colony stimulating factor 1 receptor inhibitor PLX3397 in recurrent glioblastoma: an Ivy Foundation Early Phase Clinical Trials Consortium phase II study

Depletion of microglia augments the dopaminergic neurotoxicity of MPTP

Structure-guided blockade of CSF1R kinase in tenosynovial giant-cell tumor

CSF1R inhibition by a small-molecule inhibitor is not microglia specific; affecting hematopoiesis and the function of macrophages

Putterman C (2015) Macrophage depletion ameliorates nephritis induced by pathogenic antibodies

To Kill a microglia: a case for CSF1R inhibitors

Colony-stimulating factor 1 receptor inhibition prevents microglial plaque association and improves cognition in 3xTg-AD mice

Inhibition of colony-stimulating-factor-1 signaling in vivo with the orally bioavailable cFMS kinase inhibitor GW2580

Underestimated peripheral effects following pharmacological and conditional genetic microglial depletion

Repopulated microglia are solely derived from the proliferation of residual microglia after acute depletion

Replacement of microglia in the aged brain reverses cognitive, synaptic, and neuronal deficits in mice

Repopulating microglia promote brain repair in an IL-6-dependent manner

Early-versus late-onset Alzheimer's disease in clinical practice: cognitive and global outcomes over 3 years

Clinical utility of the pathogenesis-related proteins in Alzheimer's disease

Phosphorylation of different tau sites during progression of Alzheimer's disease

Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry

Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer's disease mutations: potential factors in amyloid plaque formation

Early long-term administration of the CSF1R inhibitor PLX3397 ablates microglia and reduces accumulation of intraneuronal amyloid, neuritic plaque deposition and pre-fibrillar oligomers in 5XFAD mouse model of Alzheimer's disease

Neuron loss in the 5XFAD mouse model of Alzheimer's disease correlates with intraneuronal Abeta42 accumulation and Caspase-3 activation

Motor deficits, neuron loss, and reduced anxiety coinciding with axonal degeneration and intraneuronal Abeta aggregation in the 5XFAD mouse model of Alzheimer's disease

Neuroinflammation and microglial activation in Alzheimer disease: where do we go from here?

Can we treat neuroinflammation in Alzheimer's disease?

Microglia depletion diminishes key elements of the leukotriene pathway in the brain of Alzheimer's Disease mice

Resolution of inflammation is altered in Alzheimer's disease

Can inflammation be resolved in Alzheimer's disease?

Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease

Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families

TREM2 variants in Alzheimer's disease

Variant of TREM2 associated with the risk of Alzheimer's disease

Microglia contributes to plaque growth by cell death due to uptake of amyloid beta in the brain of Alzheimer's disease mouse model

Microglia depletion rapidly and reversibly alters amyloid pathology by modification of plaque compaction and morphologies

Pharmacological targeting of CSF1R inhibits microglial proliferation and prevents the progression of Alzheimer's-like pathology

Depletion of microglia and inhibition of exosome synthesis halt tau propagation

Microglia drive APOEdependent neurodegeneration in a tauopathy mouse model

Partial reduction of microglia does not affect tau pathology in aged mice

Colony-stimulating factor 1 receptor (CSF1R) signaling in injured neurons facilitates protection and survival

Emerging roles for CSF-1 receptor and its ligands in the nervous system

Transcriptome Profiling of layer 5 intratelencephalic projection neurons from the mature mouse motor cortex

A MAC2-positive progenitor-like microglial population is resistant to CSF1R inhibition in adult mouse brain

Parkinson's disease in the Western Pacific region

Genetics of Parkinson's disease in the polish population

The genetics of Parkinson's disease and implications for clinical practice

Non-motor symptoms in Parkinson's disease

Parkinson disease and the immune system -associations, mechanisms and therapeutics

Neuronal network activity controls microglial process surveillance in awake mice via norepinephrine signaling

Negative feedback control of neuronal activity by microglia

Microglial implication in Parkinson's disease: loss of beneficial physiological roles or gain of inflammatory functions?

Microglial activation and dopamine terminal loss in early Parkinson's disease

Protective microglia and their regulation in Parkinson's disease

Glial phagocytic clearance in Parkinson's disease

Pharmacological Targeting of microglial activation: new therapeutic approach

Targeting microglial activation states as a therapeutic avenue in Parkinson's disease

Evaluation of the neuroprotective effect of microglial depletion by CSF-1R inhibition in a Parkinson's animal model

Genetic risk underlying psychiatric and cognitive symptoms in Huntington's disease

Huntington's disease: a clinical review

Patient-reported impact of symptoms in Huntington disease

The role of microglia and astrocytes in Huntington's disease

Huntington's disease alters human neurodevelopment

Early intrathecal T helper 17.1 cell activity in Huntington disease

Therapeutic update on Huntington's disease: symptomatic treatments and emerging disease-modifying therapies

Increased central microglial activation associated with peripheral cytokine levels in premanifest Huntington's disease gene carriers

Microglial activation in the pathogenesis of Huntington's disease

Microglial depletion prevents extracellular matrix changes and striatal volume reduction in a model of Huntington's disease

The CSF1 receptor inhibitor pexidartinib (PLX3397) reduces tissue macrophage levels without affecting glucose homeostasis in mice

Microglia depletion and alcohol: transcriptome and behavioral profiles

Use of large animal models to investigate Huntington's diseases

Towards a transgenic model of Huntington's disease in a nonhuman primate

A huntingtin knockin pig model recapitulates features of selective neurodegeneration in Huntington's disease

Patient-specific models of microglia-mediated engulfment of synapses and neural progenitors

A proposal for new diagnostic criteria for ALS

Immune dysregulation in amyotrophic lateral sclerosis: mechanisms and emerging therapies

Nicotinamide riboside enhances mitochondrial proteostasis and adult neurogenesis through activation of mitochondrial unfolded protein response signaling in the brain of ALS SOD1(G93A) mice

The role of mitochondria in amyotrophic lateral sclerosis

The role of oxidative stress in degeneration of the neuromuscular junction in amyotrophic lateral sclerosis

The dual role of microglia in ALS: mechanisms and therapeutic approaches

Role of neuroinflammation in amyotrophic lateral sclerosis: cellular mechanisms and therapeutic implications

CCR2 is localized in microglia and neurons, as well as infiltrating monocytes, in the lumbar spinal cord of ALS mice

Imaging of brain TSPO expression in a mouse model of amyotrophic lateral sclerosis with (18)F-DPA-714 and micro-PET/CT

The microglial component of amyotrophic lateral sclerosis

Potential of activated microglia as a source of dysregulated extracellular microRNAs contributing to neurodegeneration in amyotrophic lateral sclerosis

Increased activation ability of monocytes from ALS patients

CSF1R blockade slows the progression of amyotrophic lateral sclerosis by reducing microgliosis and invasion of macrophages into peripheral nerves

Modifying macrophages at the periphery has the capacity to change microglial reactivity and to extend ALS survival

Diversity of immune cell types in multiple sclerosis and its animal model: Pathological and therapeutic implications

Accurate classification of secondary progression in multiple sclerosis using a decision tree

The window of opportunity for treatment of progressive multiple sclerosis

Pathogenic mechanisms associated with different clinical courses of multiple sclerosis

Intrathecal inflammation in progressive multiple sclerosis

Microglia in central nervous system inflammation and multiple sclerosis pathology

Widespread glial activation in primary progressive multiple sclerosis revealed by 18F-PBR06 PET: a clinically feasible, individualized approach

Effect of the CSF1R inhibitor PLX3397 on remyelination of corpus callosum in a cuprizone-induced demyelination mouse model

Csf1R inhibition attenuates experimental autoimmune encephalomyelitis and promotes recovery

Microglia: dynamic mediators of synapse development and plasticity

Depletion of embryonic microglia using the CSF1R inhibitor PLX5622 has adverse sex-specific effects on mice, including accelerated weight gain, hyperactivity and anxiolytic-like behaviour

Depletion of microglia in developing cortical circuits reveals its critical role in glutamatergic synapse development, functional connectivity, and critical period plasticity

Acute microglia ablation induces neurodegeneration in the somatosensory system

Microglial depletion disrupts normal functional development of adult-born neurons in the olfactory bulb

Concentration-dependent effects of CSF1R inhibitors on oligodendrocyte progenitor cells ex vivo and in vivo

Pharmacological depletion of microglia and perivascular macrophages prevents vascular cognitive impairment in Ang II-induced hypertension

Modulation of CSF-1-regulated post-natal development with anti-CSF-1 antibody

Microglia depletion fails to abrogate inflammation-induced sickness in mice and rats

PST-PIP2 deficiency in mice causes osteopenia and increased differentiation of multipotent myeloid precursors into osteoclasts

Pexidartinib, a novel small molecule CSF-1R inhibitor in use for tenosynovial giant cell tumor: a systematic review of pre-clinical and clinical development

Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial

Targeting microglia attenuates neuroinflammation-related neural damage in mice carrying human PLP1 mutations

Pexidartinib: first approved systemic therapy for patients with tenosynovial giant cell tumor

Microglia are critical in host defense against prion disease

Colonystimulating factor 1 and its receptor are new potential therapeutic targets for allergic asthma

Microglial cell depletion is fatal with low level picornavirus infection of the central nervous system

Microglia are required for protection against lethal coronavirus encephalitis in mice

2020) An early microglial response is needed to efficiently control herpes simplex virus encephalitis

Chronic immunosuppression and potential infection risks in CSF1R-related leukoencephalopathy